Product Description: Nipocalimab (M281) is a fully human, recombinant, aglycosylated IgG1 monoclonal antibody. Nipocalimab is a human deglycosylated IgG1 anti-FcRn monoclonal antibody that binds with picomolar affinity to Fc receptor (FcRn) at both endosomal pH 6.0 and extracellular pH 7.6[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]James S Castleman, et al. Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation. Br J Haematol. 2021 Feb;192(3):425-432./[2]Marinos C Dalakas, et al. The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021 Feb 26;14:1756286421997381.
CAS Number: 2211985-36-1
Molecular Weight: N/A
Compound Purity: 99.90
Research Area: Inflammation/Immunology
Solubility: H2O
Target: Others
English
Deutsch
